Predictive markers of pituitary adenoma behavior

Neuroendocrinology

Volumn 83, Issue 3-4, 2006, Pages 179-188

  Kontogeorgos, George ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Apoptosis; Ki 67; Molecular cytogenetics; p53 protein; Somatostatin receptors

Indexed keywords

CYCLOOXYGENASE 2; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); GALECTIN 3; KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TELOMERASE;

ANEUPLOIDY; APOPTOSIS; CANCER INVASION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 11; CONFERENCE PAPER; CYTOGENETICS; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MICROADENOMA; MITOSIS RATE; MONOSOMY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROLACTINOMA; TUMOR VOLUME;

ADENOMA; ANIMALS; APOPTOSIS; HUMANS; PITUITARY NEOPLASMS; PLOIDIES; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750039991     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095526     Document Type: Conference Paper

References (44)

1. Kovacs K, Horvath E: Tumors of Pituitary Gland. Atlas of Tumor Pathology, 2nd series, fascicle 21. Bethesda, Armed Forces Institute of Pathology, 1986.
2. Horvath E, Lloyd RV, Kovacs K, Sano T, Kontogeorgos G, Trouillas J, Asa SL: Plurihormonal adenoma; in DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): WHO Classification of Tumours. Pathology and Genetics. Tumours of Endocrine Organs. Lyon, IARC Press, 2004, p 35.
3. Valdemarsson S, Bramnert M, Cronquist S, Elner A, Eneroth CM, Hedner P, Lindvall-Axelsson M, Nordstrom CH, Stromblad LG: Early postoperative basal serum GH level and the GH response to TRH in relation to the long-term outcome of surgical treatment for acromegaly: a report of 39 patients. J Intern Med 1991;230:49-54.
4. Fahlbusch R, Honegger J, Buchfelder M: Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21:669-692.
5. Thapar K, Kovacs K, Scheithauer B, Stefaneanu L, Horvath E, Pernicone JP, Murray D, Laws RE Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-107.
6. Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM: The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-407.
7. Pernicone PJ, Scheithauer BW: Invasive pituitary adenoma and pituitary carcinoma; in Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (eds): Diagnosis and Management of Pituitary Tumors. Totowa, Humana Press, 2001, pp 369-885.
8. Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheihauer BW, Horvath E: Pituitary tumours: introduction; in DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): WHO Classification of Tumours. Pathology and Genetics. Tumours of Endocrine Organs. Lyon, IARC Press, 2004, pp 10-13.
9. Cross SS, Start, RD, Smith JH: Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol 1990;43:597-599.
10. Gerdes J, Lemke H, Baisch H, Wacker HH, Schab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
11. Gerdes J, Becker MHG, Key G: Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1992;168:85-87.
12. Kontogeorgos G: Innovations and controversies in the WHO classification of pituitary adenomas. Acta Neuropathol (Berl) 2006;111:73-75.
13. Rybenkov VV, Ullsperger C, Vologodskii AV, Cozzarelli NR: Simplification of DNA topology below equilibrium values by type II topoisomerases. Science 1997;277:690-693.
14. Capranico G, Kohn KW, Pommier Y: Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990;18:6611-6619.
15. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase II alpha associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
16. Münscher A, Schmid M, Saeger W, Schreiber S, Lüdecke DK: GH-, PRL-, POMC-, β-TSH-, β-LH-, β-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data. Endocr Pathol 2001;12:171-180.
17. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW: Topoisomerase II alpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 2002;15:1205-1212.
18. Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
19. Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509-519.
20. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB: Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87:2635-2643.
21. Nakabayashi H, Sunada J, Hara M: Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001;49:1193-1194.
22. Thapar K, Scheithauer B, Kovacs K, Pernicone PJ, Laws ER Jr: p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-769.
23. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-3099.
24. Vidal S, Horvath E, Kovacs K, Scheithauer BW, Lloyd RV, Kontogeorgos G: Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastruct Pathol 2001;25:85-92.
25. Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS: Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol (Berl) 2006;111:46-52.
26. Kapranos N, Kontogeorgos G, Horvath E, Kovacs K: Morphology, significance and molecular regulation of apoptosis in pituitary adenomas; in Kontogeorgos G, Kovacs K (eds): Molecular Pathology of the Pituitary. Frontiers of Hormone Research Book Series. Basel, Karger, 2004, vol 32, pp 217-234.
27. Meyer JS, Coplin MD: Thymidine labeling index, flow cytometric S-phase measurement and DNA index in human tumors. Am J Clin Pathol 1988;89:586-595.
28. Mellin W: Cytometry in tumor pathology - a critical review of methods and applications, and some results of DNA analysis. Path Res Pract 1990;186:37-62.
29. Anniko M, Tribukait B, Wersall J: DNA ploidy and cell phase in human pituitary tumors. Cancer 1984;53:1708-1713.
30. Lüdecke DK, Beck-Bornholdt HP, Saeger W, Schmidt W: Tumor ploidy in DNA histograms of pituitary adenomas. Acta Neurochir 1985;76:18-22.
31. Fitzgibbons PL, Appley A, Turner RR, Bishop P, Parker J, Breeze R, Weiss M, Apuzzo J: Flow cytometric analysis of pituitary tumors. Cancer 1988;62:1556-1560.
32. Stefaneanu L, Murray D, Kovacs K, Smyth HS: Comparative study of DNA content and interphase nucleolar organizer regions in human pituitary adenomas. Endocr Pathol 1990;1:182-187.
33. Kontogeorgos G, Kapranos N, Rologis D, Vamvassakis E, Papadopoulos N: DNA measurement in pituitary adenomas assessed on imprints by image analysis. Anal Quant Cytol Histol 1996;18:144-150.
34. Hulting AL, Askensten U, Tribukait B, Wersall J, Auer G, Grimelius L, Falkmer S, Werner S: DNA evaluation in growth hormone producing pituitary adenomas: flow cytometry versus single cell analysis. Acta Endocrinol (Copenh) 1989;121:317-321.
35. Kontogeorgos G: The art and applications of fluorescence in situ hybridization in endocrine pathology. Endocr Pathol 2000;11:123-136.
36. Kontogeorgos G, Kapranos N, Orphanidis G, Rologis D, Kokka E: Molecular cytogenetics of chromosome 11 in pituitary adenomas: a comparison of fluorescence in situ hybridization and DNA ploidy study. Hum Pathol 1999;30:1377-1382.
37. Daniel M, Aviram A, Adams EF, Buchfelder M, Berkai G, Fahlbusch R, Goldman B, Friedman E: Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J Clin Endocrinol Metab 1998;83:1801-1805.
38. Hui AB, Pang JC, Ko CW, Ng HK: Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum Pathol 1999;30:1019-1023.
39. Kallioniemi A, Kallioniemi O, Sudar D, Rutovitz D, Gray J, Waldeman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1990;258:818-821.
40. Finelli P, Giardino D, Rizzi N, Buiatiotis S, Virduci T, Franzin A, Losa M, Larizza L: Non-random trisomies of chromosomes 5,8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study. Int J Cancer 2000;86:344-350.
41. Reichlin S: Somatostatin. N Engl J Med 1983;309:1495-1501.
42. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
43. Thodou E, Kontogeorgos G, Theodosiou D, Pateraki M: Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006;59:274-279.
44. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM: Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001;86:3097-3107.